Replication-competent vesicular stomatitis viruses

Abstract

This document provides methods and materials related to vesicular stomatitis viruses. For example, replication-competent vesicular stomatitis viruses, nucleic acid molecules encoding replication-competent vesicular stomatitis viruses, methods for making replication-competent vesicular stomatitis viruses, and methods for using replication-competent vesicular stomatitis viruses to treat cancer or infectious diseases are provided.

1 - 13 . (canceled) 
     
     
         14 . A method for treating cancer, wherein said method comprises administering a composition comprising replication-competent vesicular stomatitis viruses to a mammal comprising cancer cells, wherein said vesicular stomatitis viruses comprise an RNA molecule comprising a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV N polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV P polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV M polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a Paramyxovirus F polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a Paramyxovirus H polypeptide, and a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV L polypeptide, wherein said RNA molecule lacks a nucleic acid sequence that is a template for a positive sense transcript encoding a functional VSV G polypeptide, wherein administration of said composition to said mammal is under conditions wherein said vesicular stomatitis viruses infect said cancer cells to form infected cancer cells, and wherein the number of cancer cells within said mammal is reduced following said administration. 
     
     
         15 . The method of  claim 14 , wherein said mammal is a human. 
     
     
         16 . The method of  claim 14 , wherein said RNA molecule comprises a nucleic acid sequence that is a template for a positive sense transcript encoding a NIS polypeptide. 
     
     
         17 . The method of  claim 16 , wherein said NIS polypeptide is a human NIS polypeptide. 
     
     
         18 . The method of  claim 14 , wherein said Paramyxovirus H polypeptide is a measles virus H polypeptide comprising Y481A and R533A amino acid substitutions with respect to a wild-type measles virus H polypeptide. 
     
     
         19 . The method of  claim 14 , wherein said Paramyxovirus H polypeptide comprises an amino acid sequence of a single chain antibody. 
     
     
         20 . The method of  claim 19 , wherein said single chain antibody is a single chain antibody directed to EGFR, αFR, or PSMA. 
     
     
         21 . A method for inducing tumor regression in a mammal, wherein said method comprises administering a composition comprising replication-competent vesicular stomatitis viruses to a mammal comprising a tumor, wherein said vesicular stomatitis viruses comprise an RNA molecule comprising a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV N polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV P polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV M polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a Paramyxovirus F polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a Paramyxovirus H polypeptide, and a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV L polypeptide, wherein said RNA molecule lacks a nucleic acid sequence that is a template for a positive sense transcript encoding a functional VSV G polypeptide, wherein administration of said composition to said mammal is under conditions wherein said vesicular stomatitis viruses infect tumor cells of said tumor to form infected tumor cells. 
     
     
         22 . The method of  claim 21 , wherein said mammal is a human. 
     
     
         23 . The method of  claim 21 , wherein said RNA molecule comprises a nucleic acid sequence that is a template for a positive sense transcript encoding a NIS polypeptide. 
     
     
         24 . The method of  claim 23 , wherein said NIS polypeptide is a human NIS polypeptide. 
     
     
         25 . The method of  claim 21 , wherein said Paramyxovirus H polypeptide is a measles virus H polypeptide comprising Y481A and R533A amino acid substitutions with respect to a wild-type measles virus H polypeptide. 
     
     
         26 . The method of  claim 21 , wherein said Paramyxovirus H polypeptide comprises an amino acid sequence of a single chain antibody. 
     
     
         27 . The method of  claim 26 , wherein said single chain antibody is a single chain antibody directed to EGFR, αFR, or PSMA.